{"disease":{"id":"hgg","name":"hgg"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05503797","title":"A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":254,"lead_sponsor_name":"Fore Biotherapeutics","has_results":false},{"nct_id":"NCT05538130","title":"A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":124,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04201457","title":"A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57,"lead_sponsor_name":"Pediatric Brain Tumor Consortium","has_results":false},{"nct_id":"NCT07210632","title":"Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":38,"lead_sponsor_name":"Eben Rosenthal","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}